AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

Lippman Evan sold $680K of TEVA

Lippman Evan (EVP, Business Development) sold 18,600 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $36.57 ($0.68M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lippman Evan
Published Aug 19, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Bearish
medium confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVABearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted as a lack of confidence, but could also be a pre-planned liquidity event.

02

Market read

Provides fresh insider transaction data for TEVA, useful for short-term traders.

03

What to watch

Potential upcoming corporate actions or earnings that may affect insider behavior.

Relevance 4/10Novelty 6/10Timing: filing date 2026-08-19

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$TEVABearishMedium confidence
Context

EVan Lippman, EVP of Business Development, sold 18,600 shares for $680,291 via a 10b5-1 plan, reducing his stake to 25,591 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

The sale size (~$0.68M) is material for an insider but not large enough to drive a major move; market may react cautiously.

Market effects

Sector

Minimal impact on the broader pharmaceutical sector.

Regional

Limited to markets tracking TEVA shares.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5-1 plan and not indicative of insider concern.

Key entities

  • Officer
    Lippman Evan

    EVP, Business Development at TEVA

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com